«
New radiotracer helps avoid neck dissection in patients with early head and neck cancer.»
Researchers at the National Institute of Biomedical Imaging and Bioengineering (NIBIB) have developed
a new radiotracer to diagnose prostate cancer and conducted a successful Phase I clinical trial.
Not exact matches
The study indicates that the
new agent — a PET
radiotracer — is both safe and effective.
Their discovery could aid in the synthesis of
new «
radiotracers» — chemical compounds that contain a radioactive form, or isotope, of an element — for use with a noninvasive, high - resolution 3 - D medical imaging technology known as PET (positron emission tomography) scanning.
Brookhaven scientist Joanna Fowler describes Positron Emission Technology (PET) research at BNL which for the past 30 years has focused in the integration of basic research in
radiotracer chemistry with the tools of neuroscience to develop
new scientific tools for applications in human health.
On Friday, October 19, 2012, the
New York Section of the American Chemical Society (ACS) named Brookhaven Lab's Chemistry Building an Historic Chemical Landmark, in recognition of the synthesis of 18FDG, the first successful
radiotracer for positron emission tomography (PET) imaging.
Measuring tau deposits using the novel
radiotracer 18F - AV - 1451 (18F - T807), in conjunction with 11C - PiB to measure amyloid plaques and 18F - FDG to measure regional neurodegeneration, offers
new insight into the neurodegenerative characteristics of Alzheimer's disease and shows that tau pathology may be an instrumental target for disease - modifying strategies.